Search the Newsreel

J. L. Bainbridge & Co. Inc. Makes New Investment in Agilent Technologies, Inc. $A

J. L. Bainbridge & Co. Inc. recently acquired a new stake in Agilent Technologies (NYSE:A), purchasing 27,150 shares valued at approximately $3.6 million, making it their 27th largest position. Agilent Technologies reported strong quarterly earnings, beating analyst estimates with an EPS of $1.49 and …

Should agilon health’s (AGL) Profit Rebound and Higher Guidance Prompt a Fresh Look From Investors?

Agilon health (AGL) reported a swing to profit in Q2 2026, with net income of US$17.96 million compared to a loss a year earlier, and raised its full-year 2026 revenue guidance. This improvement, driven by better medical cost management, suggests enhanced profitability without sole …

Gilead Sciences, Inc. $GILD Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its stake in Gilead Sciences by 10.9% in the second quarter, now holding 926,242 shares valued at $117 million. This move comes as Gilead reported strong quarterly revenue of $7.80 billion, exceeding analyst expectations, and announced a …

Agilent Technologies Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution

Over the last year, Agilent Technologies insiders have sold US$1.1m worth of stock, which could signal caution. While some insider buying occurred, the selling volume was higher. This activity might indicate that insiders believe the stock is fully valued or that future growth prospects …

Summitry LLC Has $88.51 Million Position in Agilent Technologies, Inc. $A

Summitry LLC slightly reduced its stake in Agilent Technologies by 1.1% in Q2 but still holds 666,332 shares valued at $88.5 million, making it their 8th largest position. Agilent Technologies reported strong Q2 earnings, surpassing analyst expectations with $1.49 EPS and $1.83 billion in …

Monument Capital Management Decreases Stake in Gilead Sciences, Inc. $GILD

Monument Capital Management significantly reduced its stake in Gilead Sciences by 56.1% in the second quarter, selling over 15,000 shares. Despite this, institutional investors collectively own 83.67% of the company, and analysts maintain a "Moderate Buy" consensus with an average price target of $158.04. …

Gilston Group Warns of Sharply Lower Interim Profit on Zipper Disposal and Rent Discounts

Gildan Activewear (GIL) adds new guarantors to 4.700% and 5.400% notes

Gildan Activewear Inc. has added HBI Branded Apparel Enterprises, LLC, Hanes Jiboa Holdings LLC, and Hanesbrands El Salvador, Ltda. de C.V. as new guarantors for its $600 million 4.700% Notes due 2030 and $600 million 5.400% Notes due 2035. This action, formalized through a …

Louisbourg Investments Inc. Has $4.79 Million Stock Holdings in Agilent Technologies, Inc. $A

Louisbourg Investments Inc. reduced its stake in Agilent Technologies by 22.2% in the second quarter, selling 10,313 shares but still holding 36,056 shares valued at approximately $4.79 million. Despite this reduction, analysts generally maintain a "Moderate Buy" rating for Agilent, with an average price …

AGL|agilon health inc|Price:89.299|Chg%:+3.039

Confluence Wealth Services Inc. Acquires 7,986 Shares of Gilead Sciences, Inc. $GILD

Confluence Wealth Services Inc. significantly increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 251.4% during the second quarter, acquiring an additional 7,986 shares, bringing its total holdings to 11,162 shares valued at $1.41 million. Gilead reported strong Q2 revenue of $7.80 billion, exceeding …

Gilead Sciences, Inc. $GILD Stock Position Lifted by Exchange Traded Concepts LLC

Gildan Activewear Faces Securities Investigations

Gildan Activewear Inc. (NYSE: GIL) is currently under multiple securities-law investigations initiated after a short seller's report questioned the company's revenue growth, distributor inventory levels, and sales practices. Several law firms are looking into potential securities fraud allegations, particularly concerning "channel stuffing," while Gildan …

Precision Trading with Ermenegildo Zegna N.v. (ZGN) Risk Zones

This article provides a detailed analysis of Ermenegildo Zegna N.v. (ZGN), highlighting weak near-term sentiment but strong long-term prospects. It outlines specific institutional trading strategies including long, breakout, and short positions with entry zones, targets, and stop losses. The analysis also incorporates multi-timeframe signal …

Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine

Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this …

Assembly Biosciences Projects Operations Funded Into 2029 With $75M Gilead Payment Due

Assembly Biosciences reported its Q2 2026 financial results, revealing a projected cash runway into 2029, bolstered by a recent $115 million financing and an anticipated $75 million payment from Gilead. The company is advancing its ABI-6250 program into Phase 2 studies for cholestatic liver …

Gilat Presents Expanded Portfolio for Tactical Unmanned Platforms

Gilat Satellite Networks Ltd., through its subsidiary Gilat Defense, has expanded its product portfolio to support tactical unmanned platforms with the introduction of RaySat’s new Viper Ka Electronically Steered Antenna (ESA). The Viper ESA is designed for resilient multi-orbit connectivity across LEO, MEO, and …

BNP Paribas Initiates Ermenegildo Zegna NV(ZGN.US) With Sell Rating, Announces Target Price $12.2

BNP Paribas has initiated coverage on Ermenegildo Zegna NV (ZGN.US) with a "Sell" rating. The firm has set a target price of $12.2 for the luxury fashion company's stock.

Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the …

Agilent Technologies stock holds steady as earnings beat and new analyst target support valuation

Agilent Technologies (A) stock is holding steady after reporting stronger-than-expected Q2 2026 earnings per share of $1.49 and 10% revenue growth to $1.83 billion. The company also issued fiscal 2026 EPS guidance between $6.00 and $6.10, which analysts anticipate will be around $6.01. A …

Ermenegildo Zegna (NYSE:ZGN) Upgraded at BNP Paribas Exane

28,409 Shares in Agilent Technologies, Inc. $A Acquired by Oak Thistle LLC

Oak Thistle LLC acquired 28,409 shares of Agilent Technologies (NYSE:A) in the second quarter, valued at approximately $3.77 million, with several other institutional investors also initiating positions. Analysts have a "Moderate Buy" consensus rating for Agilent with an average price target of $160.24, following …

Moody Lynn Lieberson & Walker LLC Has $13.33 Million Stock Position in Gilead Sciences, Inc. $GILD

Agilent Technologies, Inc. $A Shares Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB has increased its stake in Agilent Technologies (NYSE:A) by 34.4% during the second quarter, now owning 162,195 shares valued at $21.54 million. Other institutional investors also adjusted their positions in the medical research company. Agilent Technologies has received a "Moderate Buy" …

Why Gilead Sciences (GILD) Is Back In The Spotlight

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate …

Agilent Technologies, Inc. $A Shares Sold by Gateway Investment Advisers LLC

Gateway Investment Advisers LLC significantly reduced its stake in Agilent Technologies, Inc. (NYSE:A) by 82.9% in the second quarter, selling over 60,000 shares. Despite this, other institutional investors like Mitsubishi UFJ Asset Management Co. Ltd. and Mirae Asset Global Investments Co. Ltd. increased their …

Agilon Health (AGL) Stock Still Looks Below Fair Value After Raised Guidance

Agilon Health (AGL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations - Evan Smith Chief Executive Officer - Timothy O'Rourke Chief Financial Officer - Jeffrey Schwaneke Full Conference Call Transcript Operator: Hello, everyone. Thank …

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3

Agilent Technologies Inc. announced that the FDA has approved the expanded use of its PD-L1 IHC 22C3 pharmDx for Dako Omnis platform. This approval allows for identifying patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma …

Gilead Sciences (GILD) Starts AI Biomarker Research Partnership For Oncology

Gilead Sciences has partnered with Nucleai for an AI-powered biomarker research collaboration aimed at improving precision oncology and supporting Gilead's antibody drug conjugate clinical programs. This initiative seeks to standardize biomarker analyses in clinical trials to develop more tailored cancer treatments. The collaboration comes …

Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses …

Agilent Technologies, Inc. Stock 12‑Month Price Target Raised to $160.17, Implies 7% Upside

The average 12-month price target for Agilent Technologies, Inc. (A) stock has been raised from $159.33 to $160.17 by 18 analysts, with forecasts ranging from $135 to $185 per share. This new target implies a potential upside of approximately 7% from the August 11 …

Gildan Activewear Inc. stock falls Wednesday, underperforms market

Gildan Activewear Inc. (GIL) shares dropped 1.96% on Wednesday, closing at C$79.90, despite a generally favorable trading session for the Canadian market. The S&P/TSX Composite Index rose 0.51% to 36,662.14. Gildan's stock is now 20.5% below its 52-week high of C$100.44 reached on February …

Strategic Holding Group (ZGN) discloses 22.6M-share Ermenegildo Zegna N.V. position

Strategic Holding Group S.a r.l., a Luxembourg entity, has reported a beneficial ownership of 22,568,556 ordinary shares in Ermenegildo Zegna N.V. This stake represents 8.41% of the outstanding shares, based on 268,312,050 shares as of March 6, 2026. The filing indicates that Strategic Holding …

Has Agilon Health (AGL) Outpaced Other Medical Stocks This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Agilon Health (AGL) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the …

Wedge Capital Management L L P NC Raises Position in Gildan Activewear, Inc. $GIL

Wedge Capital Management L L P NC increased its stake in Gildan Activewear, Inc. by 14% during the second quarter, bringing its total holdings to 613,324 shares valued at $31.6 million. This move is part of broader institutional interest, with major investors like Janus …